BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Wyeth Pharmaceuticals (New Jersey) (WYE) Initiates Phase II And Pays Ablynx Another Milestone of $4 Million In The Tnf-Alpha Nanobody(R) Collaboration


9/30/2009 10:24:26 AM

GHENT, BELGIUM--(Marketwire - September 30, 2009) - Ablynx [Euronext Brussels: ABLX], today announced that it has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $4 million has been triggered by the initiation by Wyeth of a first Phase II multiple dose study in patients with rheumatoid arthritis (RA) for a Nanobody® targeting tumour necrosis factor alpha (TNF-alpha).

Wyeth entered into a Phase I study in healthy volunteers in December 2008 in the USA and Japan. Based on a successful conclusion of that study, where the Nanobody® was safe and well tolerated, Wyeth has today initiated a multiple dose Phase II study in RA patients. Ablynx entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals in November 2006, a deal potentially worth $212.5 million for the successful development and commercialisation of multiple products. In addition, Ablynx is eligible to receive royalties on product sales. Wyeth has exclusive rights to develop and commercialise anti-TNF-alpha Nanobodies® developed under the collaboration. TNF-alpha is a key drug target in combating inflammation related disorders such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis and ankylosing spondylitis.

Dr Edwin Moses, CEO and Chairman of Ablynx commented: "After a successful Phase I study in healthy volunteers in the USA and Japan, we are delighted that Wyeth has progressed the TNF-alpha programme into a Phase II study in patients with RA. Therapeutics targeting TNF-alpha generated $16.8 billion in sales in 2008, and Wyeth Pharmaceuticals is well positioned with its Enbrel franchise to progress this Nanobody® programme towards the market and create another great success."

                               -ends-

For more information, please contact:
For international media enquiries:
College Hill Life Sciences
Sue Charles, Justine Lamond,
Dr John McIntyre
t:   +44 (0)20 7866 7857
e:  ablynx@collegehill.com

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193
e:  edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
+44 (0)7990 570 900
e:  eva-lotta.allan@ablynx.com


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Attachments:

Complete version of the press release in English -- http://hugin.info/137912/R/1344997/322669.pdf

Copyright © Hugin AS 2009. All rights reserved.





Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES